Security key
019818202
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 11,591,136
- Total 13F value
- $4,868,277
- Share change
- +11,591,118
- SEC-reported price per share
- $0.42
- Number of holders
- 6
- Value change
- +$4,868,269
- Number of buys
- 5
- Shares outstanding
- 5,045,531
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
6
Top holders
6
ALVR full security history
Ownership snapshot
Full 13F holder table
Kalaris Therapeutics, Inc. SEC filings
Kalaris Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ALVR - Allovir, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
EcoR1 Capital, LLC
Disclosed value leader
Ansbert Gadicke
Comparable rows
1/15
Latest evidence
30 Sep 2024
13F
13D/G
3/4/5
Lead comparable stake: 8.1%
14 rows are not safely comparable across share classes.
13D/G row: EcoR1 Capital, LLC
Showing 1-6 of 15 holder rows.
Quick read
EcoR1 Capital, LLC leads the comparable SEC ownership view at 8.1%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens EcoR1 Capital, LLC's linked filing trail.
Comparable ownership
Top 1
EcoR1 Capital, LLC
8.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC |
13F
13D/G
Company
|
8.1%
from 13D/G
|
$9,131,672
11,294,585 shares
|
— | 30 Sep 2024 |
| Ansbert Gadicke |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$11,205,689
16,704,963 shares
|
— | 28 Jul 2022 |
| ElevateBio, LLC |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$11,185,433
16,674,766 shares
|
— | 28 Jul 2022 |
| GILEAD SCIENCES, INC. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$11,158,950
16,635,286 shares
|
— | 27 Jun 2023 |
| F2 MG Ltd |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$6,592,683
9,828,091 shares
|
— | 28 Jul 2022 |
| Octagon Capital Advisors LP |
13F
Company
|
—
class O/S missing
|
$9,056,817
11,202,000 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
6
Shares
11,591,136
Rows available
6
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
0
Q4 2024 holders
6
Holder diff
6
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|